Repair & Recovery
BPC-157: What the Evidence Actually Supports
A citation-first read on the most hyped repair peptide, mechanism, the rodent data, the missing human trials and the risk nobody markets.
Want to listen instead of read?
Log in or create a free account to play this narration (about 11 min) and listen to dozens of peptide research briefs, hands free.
BPC-157 is a synthetic 15-amino-acid sequence derived from a protein found in human gastric juice. It has become the most talked-about repair peptide on the internet, and also one of the most over-claimed. This brief separates what the rodent literature actually shows from what the marketing has bolted on top of it.
Key takeaways
- 01Nearly all published efficacy data is preclinical, rodent models of tendon, ligament, muscle and gut injury.
- 02The most reproducible signal is accelerated tendon-to-bone and gut mucosal healing, likely via VEGFR2/eNOS-driven angiogenesis.
- 03There are no completed peer-reviewed human efficacy RCTs for musculoskeletal repair as of this writing.
- 04Oral and injected routes both show activity in animals, which is unusual for a peptide and worth understanding.
What the molecule actually is
BPC stands for Body Protection Compound. The parent protein was isolated from gastric juice, and BPC-157 is a partial sequence of it. Unlike most peptides of similar length, it appears unusually stable in gastric acid, which is why the animal literature includes oral dosing arms that still produce measurable effects.
BPC-157
Body Protection Compound 157, PL 14736
- Dose
- Rodent studies commonly use 10 µg/kg; human protocols circulating online are extrapolations, not validated doses
- Frequency
- Once or twice daily in most animal protocols
- Route
- Intraperitoneal, intramuscular, or oral in published models
- Half-life
- Reported around 4 hours in serum in animal work
- Reconstitution
- Bacteriostatic water, added slowly down the vial wall
- Storage
- Lyophilised powder refrigerated; reconstituted material cold and used within weeks
Research context only. No human dose here is established by regulatory review.
The mechanism, as far as anyone can tell
The dominant hypothesis is angiogenic. BPC-157 upregulates VEGFR2 expression and activates the VEGFR2–Akt–eNOS pathway, increasing nitric oxide availability and driving new capillary formation into damaged tissue. Secondary effects reported include modulation of the nitric oxide system in both directions, growth-hormone receptor upregulation in tendon fibroblasts, and interaction with dopaminergic and serotonergic systems in the brain-gut axis.
What the studies show, by injury model
Selected preclinical findings
| Model | Species | Reported effect | Evidence strength |
|---|---|---|---|
| Achilles tendon transection | Rat | Faster functional recovery and tendon fibroblast outgrowth | Multiple labs, consistent |
| Medial collateral ligament | Rat | Improved biomechanical load tolerance at healing site | Single-group replication |
| NSAID-induced gut lesions | Rat | Marked mucosal protection and lesion reduction | Strong and repeated |
| Crush muscle injury | Rat | Improved muscle function scores | Limited |
| Human musculoskeletal injury | Human | No completed published efficacy RCT | Absent |
Safety signals and what is genuinely unknown
Acute toxicity in rodents is low; studies routinely fail to establish an LD50 at doses far above the effective range. That is reassuring for acute exposure and says nothing about chronic human use. The honest summary is that the safety file is thin rather than alarming.
- No published human pharmacokinetic data at commonly used doses.
- Angiogenesis promotion is unstudied in people with existing undiagnosed neoplasia.
- Grey-market purity is highly variable; independent third-party assays regularly find under-dosed or contaminated vials.
- It is prohibited at all times under the WADA S0 category for tested athletes.
The gap between what BPC-157 has been shown to do in rats and what it is sold as doing in humans is the largest of any peptide we have reviewed.
How to read a BPC-157 claim
- Ask which species the underlying study used. If the answer is rat, the claim is a hypothesis.
- Ask whether the dose was scaled by body surface area or just multiplied. Most consumer protocols do the latter, which is wrong.
- Ask whether the endpoint was functional recovery or a histology slide. Those are not the same claim.
- Ask for the certificate of analysis with the mass spec trace, not a purity percentage on a web page.
Reference
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract
Sikiric P, et al. · Current Pharmaceutical Design · 2011
Foundational review of the gut-protective work from the group that has published most of the BPC-157 literature.
Reference
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Chang CH, et al. · Journal of Applied Physiology · 2011
One of the cleaner mechanistic tendon papers, including fibroblast outgrowth assays.
Reference
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
Hsieh MJ, et al. · Journal of Molecular Medicine · 2017
The core angiogenesis mechanism paper underpinning most current claims.
Go deeper
The appraisal guide we use internally when reading a new peptide paper.
Common questions
Is BPC-157 approved for human use anywhere?
No. It is not an approved drug in the United States, European Union, United Kingdom or Australia. In 2023 the FDA moved it to a category that bars compounding pharmacies from using it.
Does oral dosing actually work?
In rodents, oral administration produced effects in gut and, in some papers, systemic injury models. Whether that translates to humans at consumer doses is unstudied.
Is it detectable in drug testing?
Yes. It falls under WADA's S0 non-approved substances category and assays exist.
Start a conversation
Debate this
Peptide science moves faster than the consensus around it. Post it with a question and see what people who disagree with you have to say.
Genuine question for anyone deeper in this than me: is this accurate?
This question is attached to your post, along with a link back to the brief.
Tip: highlight any sentence in the article to debate that exact line.
Read next
GLP-1 Receptor Agonists: The Mechanism, The Trials, The Trade-offs
Semaglutide, tirzepatide and what comes next, incretin biology, the actual trial numbers, and the questions the headlines skip.
How to Read a Peptide Certificate of Analysis
Purity percentage, net peptide content, HPLC traces and mass spec, a plain-language guide to verifying what is actually in the vial.
GHK-Cu: The Copper Peptide With Actual Human Data
Where the dermatology evidence is genuinely strong, where the systemic claims collapse, and why formulation decides the outcome.